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Innate immunity represents the ﬁrst line of defense against pathogens and plays key roles
in activation and orientation of the adaptive immune response.The innate immune system
comprises both a cellular and a humoral arm. Components of the humoral arm include sol-
uble pattern recognition molecules (PRMs) that recognize pathogen-associated molecular
patterns and initiate the immune response in coordination with the cellular arm, therefore
acting as functional ancestors of antibodies.The long pentraxin PTX3 is a prototypic soluble
PRM that is produced at sites of infection and inﬂammation by both somatic and immune
cells. Gene targeting of this evolutionarily conserved protein has revealed a non-redundant
role in resistance to selected pathogens. Moreover, PTX3 exerts important functions at
the crossroad between innate immunity, inﬂammation, and female fertility. The human
PTX3 protein contains a single N-glycosylation site that is fully occupied by complex type
oligosaccharides, mainly fucosylated and sialylated biantennary glycans. Glycosylation has
been implicated in a number of PTX3 activities, including neutralization of inﬂuenza viruses,
modulation of the complement system, and attenuation of leukocyte recruitment. There-
fore, this post translational modiﬁcationmight act as a ﬁne tuner of PTX3 functions in native
immunity and inﬂammation. Here we review the studies on PTX3, with emphasis on the
glycan-dependent mechanisms underlying pathogen recognition and crosstalk with other
components of the innate immune system.
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INTRODUCTION
The innate immune system has evolved to speciﬁcally recognize
and eradicate potentially harmful microorganisms, thus provid-
ing the ﬁrst line of defense against pathogens. Evolutionarily older
than the adaptive immune system, innate immunity plays key roles
in activation and orientation of adaptive immunity that provides
the immunological memory. Components of the innate immune
system that are involved in pathogen recognition and initiation of
the immune response are germline-encoded receptors known as
pattern recognition molecules (PRMs). These receptors recognize
microbes or microbial moieties collectively named pathogen-
associated molecular patterns (PAMPs; Iwasaki and Medzhitov,
2010). PRMs can also sense endogenous ligands termed “danger-
associated molecular patterns (DAMPs),” which are released by
host cells upon tissue damage during, for example, infection,
inﬂammation, and tumor growth (Matzinger, 2002). As numer-
ous PAMPs and DAMPs are glycans themselves or accommodate
glycan structures, PRMs are mostly comprised of glycan-binding
proteins or lectins. These include C-type lectins, siglecs, and
galectins, which contain one or more carbohydrate-recognition
domains (CRDs) that are responsible for sugar recognition (van
Kooyk and Rabinovich, 2008). In addition, most PRMs are glyco-
proteins whose glycosidicmoietymight have a dramatic impact on
protein targeting andactivity. For instance, some toll-like receptors
(TLRs), such as TLR2 and TLR4, require glycosylation for correct
cell compartmentalization (da Silva Correia and Ulevitch, 2002;
Weber et al., 2004), and inhibition of glycosylation prevents TLR3-
induced NF-κB activation, although it does not affect expression
and trafﬁcking of this receptor (Sun et al., 2006).
Considering cellular localization and function, PRMs are clas-
siﬁed into two major groups: (i) cell-associated receptors, which
are localized in different cellular compartments and include
endocytic receptors, such as scavenger receptors (Murphy et al.,
2005), signaling receptors, such as TLRs (Akira et al., 2006) and
nucleotide-binding oligomerization domain (NOD)-like recep-
tors (NLR; Meylan et al., 2006), and (ii) ﬂuid phase molecules
or opsonins, which represent the functional ancestors of anti-
bodies and are involved in pathogen opsonization, complement
activation, and self versus modiﬁed-self discrimination (Bot-
tazzi et al., 2010). Fluid phase PRMs are essential effectors and
modulators of the innate resistance in animals and humans, and
form a heterogeneous group of molecules that includes collectins,
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ﬁcolins, and pentraxins (Fujita, 2002; Holmskov et al., 2003;
Bottazzi et al., 2006).
Conserved in evolution from arachnids to humans, pentraxins
are pivotal components of the humoral arm of innate immunity
with a distinctive multimeric structure. Based on the primary
structure of the composing protomers, pentraxins are divided into
two groups: short and long pentraxins (Deban et al., 2011). C-
reactive protein (CRP) and serum amyloid P component (SAP)
are prototypic short pentraxins, whereas pentraxin 3 (PTX3)
and other subsequently identiﬁed proteins represent the long
pentraxin arm of the family (Garlanda et al., 2005).
Here we review past and present literature on this family of
proteins, with major emphasis on the long pentraxin PTX3 and
the glycan-dependent mechanisms underlying its functions in
pathogen recognition and crosstalk with other components of the
innate immune system.
THE SHORT PENTRAXINS
Pentraxins are distinctively characterized by the presence in their
carboxy-terminal region of a∼200 amino acid domain containing
a highly conservedmotif of primary sequence known as pentraxin
signature (HxCxS/TWxS,where x is any amino acid). In the 1930s,
CRP was the ﬁrst puriﬁed PRM, which was named after its ability
to bind in a calcium-dependent fashion the C-polysaccharide of
Streptococcus pneumoniae (Tillet and Francis, 1930; Abernethy and
Avery, 1941). Human SAP was subsequently identiﬁed as a closely
related protein (i.e., with 51% sequence identity to human CRP;
Emsley et al., 1994). Orthologous proteins to human CRP and
SAP have also been described in the hemolymph of the arthropod
Limulus polyphemus, where they are involved in recognition and
killing of pathogens (Liu et al., 1982; Armstrong et al., 1996; Shrive
et al., 1999).
Both short pentraxins are 25 kDa proteins with a common
structural organization that comprises 5 or 10 identical subunits
arranged in a pentameric radial symmetry (Rubio et al., 1993;
Emsley et al., 1994). Each of the composing subunits displays a
lectin-like fold with two-layered β sheet in a ﬂattened jellyroll
topology (Thompson et al., 1999). The human CRP protein is
not glycosylated, whereas human SAP is traditionally described
as homogeneously modiﬁed with sialylated biantennary complex
type glycans (Pepys et al., 1994). However, this view has been chal-
lenged by studies reporting microheterogeneity of the glycosidic
moiety of SAP due to loss of one or both terminal sialic acid
residues (Weiss et al., 2011). In this regard, it has been proposed
that the loss of sialic acid might cause a reorientation of SAP
oligosaccharides, which in turn induces conformational changes
in the protein tertiary and quaternary structure. Therefore, it is
conceivable that the glycosylation status of SAP might affect the
structure/function relationships of this short pentraxin (Ashton
et al., 1997; Siebert et al., 1997).
C-reactive protein and SAP are the main acute-phase reactants
in human and mouse, respectively. CRP is barely detectable in the
plasma of healthy human adults (≤3 mg/l) but its concentration
increases by as much as 1000-fold in several pathological condi-
tions. As opposed to this, the concentration of human (but not
murine) SAP is substantially invariant (30–50 mg/l), even during
the early acute-phase response. Human CRP and SAP are both
produced by hepatocytes, where the pro-inﬂammatory cytokine
IL-6 is a major inducer of CRP both on its own and in synergy
with IL-1 (Pepys and Hirschﬁeld, 2003).
Short pentraxins are important players in humoral innate
immunity, where they have been described to recognize a num-
ber of diverse ligands, mostly in a calcium-dependent manner.
As mentioned above, the ﬁrst reported ligand of CRP is the C-
polysaccharide of Streptococcus pneumoniae. This interaction is
mediated by phosphorylcholine (PC), a major constituent of the
C-type capsule polysaccharides (Tillet and Francis, 1930; Aber-
nethy and Avery, 1941). CRP recognizes additional pathogens,
including fungi, yeasts, and bacteria, thus promoting phagocyto-
sis and resistance to infection (Szalai, 2002). Consistent with this,
CRP transgenic (Tg) mice are resistant to infection with Strep-
tococcus pneumoniae, displaying longer survival time and lower
mortality rate than normal littermates (Szalai et al., 1995). SAP
is a calcium-dependent lectin originally puriﬁed based on its
binding to the agarose component 4,6-cyclin pyruvate acetal of
β-D-galactose (Hind et al., 1984). Like CRP, SAP binds a number
of bacteria, such as Streptococcus pyogenes and Neisseria meningi-
tidis (Hind et al., 1985; Noursadeghi et al., 2000). In addition it has
been shown that SAP acts as β inhibitor against inﬂuenza virus,
binding in a calcium-dependent fashion to mannose-rich glycans
on the viral hemagglutinin (HA) to inhibit both hemagglutination
and viral infectivity (Andersen et al., 1997; Horvath et al., 2001).
Furthermore, SAP has been described to prevent lipopolysaccha-
ride (LPS)-mediated complement activation and LPS toxicity (de
Haas et al., 1998, 2000; Noursadeghi et al., 2000). However, the
relationship between ligand binding and function of these pro-
teins is still a matter of debate (Noursadeghi et al., 2000; Szalai
et al., 2000; Suresh et al., 2007).
The short pentraxins participate in activation and regulation
of the three complement pathways (i.e., classical, lectin, and alter-
native), by interacting with C1q (CRP and SAP; Roumenina et al.,
2006), ﬁcolins (CRP; Ng et al., 2007; Tanio et al., 2009), and fac-
tor H (CRP; Jarva et al., 1999; Mihlan et al., 2009; Okemefuna
et al., 2010). It has been suggested that complement activation by
short pentraxinsmight favor removal of the apoptotic debris, with
potential implications in preventing the onset of autoimmune dis-
eases (Nauta et al., 2003b). Speciﬁc and saturable binding to all
three classes of Fcγ receptors (FcγR) has been demonstrated for
both CRP and SAP, where these interactions mediate phagocyto-
sis of apoptotic cells and microorganisms (Bharadwaj et al., 1999,
2001; Mold et al., 2002; Lu et al., 2008). Therefore, pentraxins can
activate both complement and FcγR pathways, which resembles
the functional properties of antibodies.
THE LONG PENTRAXIN PTX3
Pentraxin 3 is the prototypic longpentraxin thatwas ﬁrst identiﬁed
in the early 1990s as a cytokine-inducible gene in endothe-
lial cells and ﬁbroblasts (Breviario et al., 1992; Lee et al., 1993).
Long pentraxins have an unrelated amino-terminal region cou-
pled to a 203 amino acids long carboxy-terminal pentraxin-like
domain. Despite the sequence homology, long pentraxins dif-
fer from short pentraxins in gene organization, chromosomal
localization, cellular source, inducing stimuli and recognized lig-
ands. Other members of the long pentraxin subfamily have been
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identiﬁed, including guinea pig apexin (Reid and Blobel, 1994),
neuronal pentraxin 1 (NPTX1 or NP1; Omeis et al., 1996), neu-
ronal pentraxin 2 (NPTX2, also called Narp or NP2; Hsu and
Perin, 1995), and the transmembrane protein neuronal pentraxin
receptor (NPTXR; Dodds et al., 1997). In an attempt to ﬁnd new
pentraxin domain-containing proteins, we have recently identiﬁed
a new long pentraxin, which we named PTX4. Like other mem-
bers of this family, the gene encoding PTX4 is well conserved from
mammals to lower vertebrates. However, PTX4 has a unique pat-
tern of mRNA expression, which is distinct from that of other long
pentraxins (Martinez de la Torre et al., 2010).
GENE ORGANIZATION AND EXPRESSION
The human PTX3 gene has been localized on chromosome 3
band q25 and is organized in three exons, coding respectively
for the leader peptide, the N-terminal domain and the pentraxin
domain, separated by two introns. The murine gene presents the
same structural organization and is located on chromosome 3.
The proximal promoters of both human and murine PTX3 genes
share numerous potential enhancer-binding elements, including
Pu1, AP-1, NF-κB, SP1, and NF-IL-6 sites (Breviario et al., 1992;
Altmeyer et al., 1995; Basile et al., 1997).
Pentraxin 3 expression is rapidly induced in a variety of addi-
tional cell types by several stimuli, such as cytokines (e.g., IL-1β,
and TNF-α), TLR agonists, microbial moieties (e.g., LPS, OmpA,
and lipoarabinomannans), and intact microorganisms (Bottazzi
et al., 2009). Oxidized and enzymatically modiﬁed low density
lipoproteins (ox-LDL) promote PTX3 production in endothelial
cells and human primary vascular smooth muscle cells (SMCs;
Presta et al., 2007). Similar inﬂammatory signals induce PTX3
expression in other cell types, including myeloid dendritic cells
(DCs), macrophages, kidney epithelial cells, synovial cells, chon-
drocytes, adipocytes, alveolar epithelial cells, glial cells, mesangial
cells, and granulosa cells (Bottazzi et al., 2009). PTX3 is con-
stitutively stored in the speciﬁc granules of neutrophils and is
released in response to TLR engagement by microorganisms or
TLR agonists (Jaillon et al., 2007; Maina et al., 2009). The released
protein can partially localize in neutrophil extracellular traps
(NETs) and neutrophil-associated PTX3 promotes the genera-
tion of an effective antimicrobial microenvironment (Jaillon et al.,
2007). Constitutive expression of PTX3 has been reported in both
human andmurine lymphatic endothelial cells (Sironi et al., 2006),
whereas resting T and B lymphocytes and natural killer cells do
not produce PTX3 mRNA.
Different signaling pathways can affect PTX3 production,
depending on cell type and/or stimuli. For instance, IFN-γ inhibits
PTX3 production in DCs, monocytes, and macrophages, while
IL-10 ampliﬁes LPS-induced PTX3 expression (Doni et al., 2006;
Maina et al., 2009). IL-4, dexamethasone, 1α, 25-dihydroxivitamin
D3, and prostaglandin E2 also inhibit LPS-induced PTX3 in
myeloid DCs (Doni et al., 2006). PTX3 expression in a model of
acute myocardial ischemia is controlled by the NF-κB pathway
(Salio et al., 2008), while induction of the protein by TNF-α in
lung epithelial cells involves the c-Jun N-terminal kinase (JNK)
pathway (Han et al., 2005). Moreover, production of PTX3 in
endothelial cells that is induced by high-density lipoproteins
(HDL) requires the activation of the PI3K/Akt pathway through
G-coupled lysosphingolipid receptors (Norata et al., 2008). Glu-
cocorticoid hormones (GCs) induce or enhance PTX3 production
in non-hematopoietic cells (e.g., ﬁbroblasts and endothelial cells),
but inhibit PTX3 production in hematopoietic cells (e.g., DCs and
macrophages; Doni et al., 2008).
PROTEIN STRUCTURE AND GLYCOSYLATION
The human PTX3 is a multimeric glycoprotein whose composing
subunits are made of 381 amino acids, including a 17-residue
signal peptide (Breviario et al., 1992). PTX3 primary sequence
is highly conserved among animal species (human and murine
PTX3 sharing 92% of conserved amino acid residues), suggesting
a strong evolutionary pressure to maintain its structure/function
relationships. Like other members of the long-pentraxin family,
PTX3 is composed of a uniqueN-terminal region and a 203 amino
acid C-terminal domain homologous to the short pentraxins CRP
and SAP (Figure 1A; Bottazzi et al., 1997).
The N-terminal region (residues 18–178 of the preprotein)
is unrelated to any known protein structure. Nevertheless, sec-
ondary structure predictions indicate that this part of the protein
is likely to form four α-helices, three of which (amino acids 78–97,
109–135, and 144–170) are probably involved in the formation
of coiled-coil structures (Presta et al., 2007; Inforzato et al., 2010;
Figures 1A,B). As stated above, the C-terminal domain of PTX3
(residues 179–381 of the preprotein) is homologous to the short-
pentraxins CRP and SAP,with up to 57% similarity (Bottazzi et al.,
1997). Therefore, three-dimensional models of this domain have
been generated that are based on the crystallographic structures
of CRP (PDB ID: 1b09) and SAP (PDB ID: 1sac; Goodman et al.,
1996; Introna et al., 1996; Inforzato et al., 2006). Here we report
a CRP-derived model (Figure 1A) that shows the pentraxin-like
domain of PTX3 to adopt a β-jelly roll topology, similar to that
found in legume lectins.
A single N-glycosylation site has been identiﬁed in the C-
terminal domain of PTX3 at Asn220. This is fully occupied by
complex type oligosaccharides, mainly fucosylated and sialylated
biantennary sugars with aminor fraction of tri- and tetrantennary
glycans. Based on three-dimensional models of the glycosylated
C-terminal domain, we have proposed that the PTX3 oligosaccha-
rides make contacts to polar and basic amino acids at the protein
surface (i.e., Lys214, Glu252, Lys255, and Arg332) mainly through
terminal residues of sialic acid (Figure 1D). These interactions are
lost when sialic acid is removed and protein sites become accessible
that are potentially relevant to ligands recognition and/or modiﬁ-
cations of the PTX3 tertiary/quaternary structure (Inforzato et al.,
2006). Interestingly, we have found that the relative content of bi-,
tri-, and tetrantennary oligosaccharides and the level of sialylation
are highly variable amongst PTX3 isolates from different cellu-
lar sources, thus suggesting that the glycosylation pattern of this
long pentraxin might change depending on cell type and inducing
stimuli. This might have important functional implications given
that the glycosidic moiety of PTX3 has been involved in a number
of biological activities as discussed below.
In addition to themultidomain organization, the human PTX3
protein shows a complex quaternary structure with eight pro-
tomer subunits assembled into high order oligomers stabilized by
disulﬁde bonds (Inforzato et al., 2008; Figure 1B). Based on data
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FIGURE 1 | Model of the PTX3 protein and its glycosylation. (A)
Schematic representation of the PTX3 protomer subunit showing the
N-terminal domain in yellow, followed by the globular pentraxin domain in red.
Positions of the Cys residues, the N-glycosylation site at Asn220 and the
pentraxin signature motif are indicated. Arrows point to a topological drawing
of the N-terminal domain, which is believed to be composed of a globular
region and three α-helical segments (α1, α2, and α3), and a three-dimensional
model of the C-terminal pentraxin domain based on the crystal structure
of C-reactive protein (Protein Data Bank ID: 1b09). (B) Disulﬁde bond
organization of the PTX3 octamer. Highlighted are the Cys residues that
participate in disulﬁde bond formation. The α-helical regions of the N-terminal
domains are predicted to form coiled-coil-like structures, which are
hypothesized to adopt either an extended (bottom) or a compact (top)
conformation. (C) Different views of the SAXS scattering envelope and a
schematic model of PTX3 based on the two different structural arrangements
proposed for the N-terminal domain. The α-helical segments of the N-terminal
domain are depicted as yellow rods. The C-terminal pentraxin domains
are in red. (D) Molecular dynamics simulations indicate that the PTX3
oligosaccharides, here represented by a core monofucosylated and
desialylated biantennary glycan, can adopt different conformations (orange,
green, and purple), where terminal residues of sialic acid can contact speciﬁc
amino acids (ball-and-stick) at the protein surface (see text for details).
from electron microscopy (EM) and small angle X-ray scattering
(SAXS), we have generated a low-resolution model of the pro-
tein that shows the composing subunits to fold into an elongated
structure with a large and a small domain interconnected by a stalk
region (Inforzato et al., 2010; Figure 1C). This oligomeric state and
the asymmetric shape of themoleculemakePTX3unique amongst
pentraxins. Indeed, it displays pseudo 4-fold symmetry along
its longitudinal axis, in sharp contrast to the typical pentameric
arrangement of the classical short pentraxins. The structural deter-
minants of the PTX3 quaternary organization aremainly localized
in the protein N-terminal domain, where this region mediates the
association of protomers into tetramers via both covalent (i.e.,
disulﬁde bonds) and non-covalent (i.e., inter-chain coiled-coils)
interactions (see Figure 1B). Although a detailed discussion of the
PTX3 structure is beyond the scopes of this review, evidence has
been provided that the quaternary structure of this long pentraxin
is fundamental inmediating its binding properties and, ultimately,
its biological functions (Inforzato et al., 2011).
PTX3 LIGANDS AND THE ROLE OF GLYCANS
The structural complexity and modular nature of PTX3, as
described above, probably explain the rather broad spectrum of
ligands of this long pentraxin and the diversity of its biological
roles as compared to the short pentraxins (Table 1). Here we
discuss the most relevant ligands of PTX3 based on the func-
tional outcome of their interaction with this protein, with major
emphasis on complement regulation, inﬂammation, andpathogen
recognition. An effort has been made to revisit the PTX3 interac-
tome in the light of the role that glycosylation plays in modulating
and, in certain cases, dictating the protein functions.
INTERACTION WITH COMPLEMENT
Classical pathway
The ﬁrst described and best characterized ligand of PTX3 is
the complement component C1q (Bottazzi et al., 1997; Nauta
et al., 2003a). PTX3 binds to plastic-immobilized C1q (Nauta
et al., 2003a; Roumenina et al., 2006), and, unlike the classical
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Table 1 | Ligand specificity of CRP, SAP, and PTX3.
Ligand CRP SAP PTX3
Complement components
C1q + + +
Factor H + NT +
C4BP + + +
M-, L-ﬁcolin + − +
MBL − + +
Extracellular matrix proteins
TNF-stimulated gene-6 (TSG-6) NT NT +
Inter-α-trypsin-inhibitor (IαI) − NT +
Hyaluronan NT NT −
Laminin + + −
Collagen IV NT + −
Fibronectin + + −
Growth factors
FGF2 +/− NT +
FGF1 and FGF4 NT NT −
Membrane moieties
Phosphocholine (PC) + − −
Phosphoethanolamine (PE) − + −
LPS − + −





Pseudomonas aeruginosa NT NT +
Klebsiella pneumoniae NT NT +
Salmonella typhimurium − + +
Fungi and yeasts
Aspergillus fumigatus + NT +
Saccharomyces cerevisiae (Zymosan) + + +
Paracoccidioides brasiliensis NT NT +
Viruses
Inﬂuenza virus − + +
Human cytomegalovirus (HCMV) NT NT +
NT, not tested.
pentraxins, this interaction is calcium-independent and does not
require previous aggregation of PTX3. Other components of the
classical pathway of complement, such asC3 andC4, are not recog-
nized by PTX3 (Bottazzi and Deban, unpublished observations).
Interaction of C1q with plastic-immobilized PTX3, an experi-
mental condition that mimics the surface of microbes, results in
activation of the classical complement cascade, assessed as C3 and
C4 deposition. On the other hand, the presence of PTX3 in solu-
tion causes a dose-dependent inhibition of the C1q hemolytic
activity (Nauta et al., 2003a). These data indicate that PTX3 may
exert a dual role and contrasting effects on complement activation:
it supports clearance of material that is able to bind PTX3, such as
microbes, while on the other hand itmay protect against unwanted
complement activation in the ﬂuid phase (Inforzato et al., 2012).
The apparent ambivalence of PTX3 might have important
implications in apoptosis, where rapid and efﬁcient clearance of
apoptotic cells by phagocytes is necessary to avoid tissue damage
due to release of the pro-inﬂammatory content of dying cells (Jean-
nin et al., 2008). PTX3 and C1q bind apoptotic cells with similar
kinetics, interacting with different binding sites and remaining
stably associated to the apoptotic cell membrane (Baruah et al.,
2006). The interaction of PTX3 with C1q in the ﬂuid phase pre-
vents C1q binding and C3 deposition onto apoptotic cells as well
as the C1q-mediated phagocytosis of apoptotic cells by DCs and
phagocytes (Rovere et al., 2000; van Rossum et al., 2004; Baruah
et al., 2006). In contrast, when PTX3 is incubated with apoptotic
cells, it enhances the deposition of both C1q and C3 on the cell
surface (Nauta et al., 2003b). In addition, membrane-associated
PTX3 acts as an “eat-me” molecule in promoting phagocytosis
of late apoptotic neutrophils, as opposed to the soluble form of
PTX3 that inhibits this process (Jaillon et al., 2009). This view
is supported by data from an in vivo murine model of systemic
lupus erythematosus, where it has been shown that PTX3 fosters
the rapid clearance of apoptotic T cells by peritoneal macrophages
(Lech et al., 2011).
Interestingly, we have reported that the glycosylation status of
PTX3modulates the protein interaction with C1qmostly through
the terminal residues of sialic acid. In fact, either desialylation or
complete deglycosylation of the long pentraxin equally increase
its binding to C1q (Inforzato et al., 2006). Consistent with this,
hydrolysis of the terminal residues of sialic acid enhances the
PTX3-dependent activation of the classical pathway of comple-
ment, as assessed by C3 and C4 deposition on PTX3-coated
surfaces. Furthermore, in the ﬂuid phase desialylated PTX3 is a
stronger inhibitor of the C1q hemolytic activity than the fully gly-
cosylated protein. Therefore the strengthening of PTX3 binding
to C1q that occurs upon removal of sialic acid is independent of
the way the long pentraxin is presented (i.e., either immobilized or
in solution). Also, sialylation of the PTX3 oligosaccharides might
provide a strategy to ﬁne tune both the activating and inhibitory
activities of this long pentraxin on the classical complement
cascade (Figure 2).
Lectin pathway
We have recently found a direct interaction of PTX3 with ﬁcolin-
2, also known as L-ﬁcolin (Ma et al., 2009), and ﬁcolin-1, also
named M-ﬁcolin (Gout et al., 2011), where these molecules are
major soluble receptors of the lectin pathway of complement. Both
ﬁcolins are ligands of CRP also, and a functional cooperation has
been described with this short pentraxin that boosts complement-
mediated antimicrobial activities (Ng et al., 2007; Zhang et al.,
2009). Ficolin-1 and -2 bind PTX3 in a calcium-dependent fash-
ion through their ﬁbrinogen (FBG)-like domain. Ficolin-1 is a
sialic acid-binding lectin; indeed enzymatic desialylation of PTX3
strongly impairs recognition of this long pentraxin by ﬁcolin-1.
Also, mutants of this lectin with reduced binding to sialic acid
display defective recognition of PTX3 (Gout et al., 2011). Ficolin-
1 binds Aspergillus fumigatus and this interaction is strengthened
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FIGURE 2 | Glycosylation as a tuner of PTX3 functions in innate
immunity. A number of both somatic and immune cell types produce
PTX3 at sites of infection/inﬂammation. The glycosylation status of PTX3
(e.g., branching and sialylation) might change depending on cellular
source and inducing stimuli (a). In addition, the protein oligosaccharides
might undergo processing by glycosidases, including neuraminidase,
which are expressed or mobilized on the surface of both pathogens
and host cells (e.g., neutrophils) (b). Desialylated PTX3 has higher
afﬁnity for C1q but loses recognition of ﬁcolin-1 and inﬂuenza
virus (c).
by PTX3 and vice versa. Likewise, the ﬁcolin-2-dependent depo-
sition of complement components on the surface of A. fumigatus
is enhanced by PTX3 (see below). This effect is alleviated by a
common amino acid change in the FBG-like domain of ﬁcolin-
2, which affects recognition of N-acetyl-D-glucosamine (GlcNAc)
and PTX3 (Ma et al., 2009). PTX3 and ﬁcolin-2 may recruit each
other to the surface of recognized microbes and amplify synergis-
tically complement-mediated innate responses. PTX3 also triggers
ﬁcolin-1-dependent activation of the lectin complement pathway,
although the potential physiological implications of this interac-
tion remain to be determined (Gout et al., 2011). The crosstalk
between PTX3 and ﬁcolins is a remarkable example of how sol-
uble PRMs can communicate through a common glycan code,
where the functional information that is contained in the glycan
structures of PTX3 is read and executed by the ﬁcolins (Figure 2)
Recently an interaction of PTX3 with mannose-binding lectin
(MBL), amolecule with structural and functional similarities with
C1q and the ﬁcolins, has been described (Ma et al., 2011). PTX3–
MBL interaction occurs in a calcium-dependent manner and
involves the MBL collagen-like domain. Formation of the MBL–
PTX3 complex recruits C1q to Candida albicans and enhances C4
and C3 deposition as well as phagocytosis of this pathogen (Ma
et al., 2011).
Complement regulation
In addition to components of the classical and lectin pathways
of complement, PTX3 has been described to interact with fac-
tor H (FH; Deban et al., 2008), the main soluble regulator of the
alternative pathway of complement activation, and with the clas-
sical and lectin pathway regulator C4b-binding protein (C4BP;
Braunschweig and Jozsi, 2011). Two binding sites for PTX3 are
present on FH: the primary binding site is located on FH short
consensus repeat (SCR) domains 19–20, which interact with the
N-terminal domain of PTX3, while a secondary site on SCR7
binds the glycosylated PTX3 pentraxin domain. In agreement,
SCR7 has been also recognized as the CRP-binding site on FH
(Jarva et al., 1999; Okemefuna et al., 2010). PTX3-bound factor H
remains functionally active, and PTX3 enhances factorH and iC3b
deposition on apoptotic cells. These observations suggest that the
interaction of PTX3 with factor Hmodulates the alternative path-
way activation by promoting factor H deposition on PTX3-coated
surfaces and preventing exaggerated complement activation. The
interaction with FH is strongly affected by PTX3 glycosylation,
as indicated by the observation that deglycosylation of this long
pentraxin impairs its binding to FH (Deban et al., 2008). It is there-
fore licit to speculate that the PTX3-dependent modulation of FH
activity might be altered by the glycosylation status of the long
pentraxin as discussed above for the C1q–PTX3 crosstalk.
Similarly to CRP and SAP, PTX3 binds C4BP (Braunschweig
and Jozsi, 2011). This interaction is dependent on the presence of
Ca2+ and inhibited byC1q andﬁcolin-2 but not by FH. Interaction
of PTX3 with C4BP occurs without interfering with the cofactor
activity of C4BP in the ﬂuid phase. PTX3 can recruit C4BP on
ECM and on apoptotic cells, where it can increase the rate of
C4b-inactivation. In parallel, the deposition of the lytic C5b-9 ter-
minal complex is reduced in the presence of PTX3 (Braunschweig
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and Jozsi, 2011). Thus PTX3 can recruit both complement regu-
lators, FH and C4BP, to limit excessive complement activation on
apoptotic cells.
Together, these observations suggest a dual role for PTX3 in the
regulation of complement-mediated immune responses. Inter-
play with key components of the three complement pathways
(i.e., C1q, ﬁcolins, MBL, and factor H) points to PTX3 as an
important player of the complex network of interactions that con-
trol complement functions. In addition, the functional outcome
of these interactions is dependent on the glycosylation status of
PTX3.
INFLAMMATION
It has been shown that PTX3 plasma levels increase rapidly and
dramatically in different pathological contexts. Overexpression of
PTX3 confers to Tg mice greater resistance than wild-type ani-
mals to LPS toxicity and to cecal ligation and puncture (Dias et al.,
2001). PTX3 can alsomodulate inﬂammation in sterile conditions.
In agreement, PTX3 deﬁciency is associated to more severe tissue
damage in experimental models of kainate-induced seizures (Rav-
izza et al., 2001), cardiac ischemia and reperfusion (Salio et al.,
2008), pleurisy and acute lung and kidney injury (Deban et al.,
2010; Han et al., 2012; Lech and Garlanda, unpublished obser-
vation). Lack of PTX3 promotes autoimmune lung damage in
Fas-deﬁcient (lpr) mice (Lech et al., 2011), and accumulation of
macrophages, neutrophils and CD3+ cells. Finally, deﬁciency of
PTX3 on an apolipoprotein E knock-out background is associated
with increased atherosclerosis, macrophage accumulation within
the plaque, and a more pronounced inﬂammatory proﬁle in the
vascular wall (Norata et al., 2009). Higher macrophage and neu-
trophil accumulation has been also observed after coronary artery
ligation and reperfusion in ptx3−/− mice, associated to greater
myocardial lesion, higher no-reﬂow area, and more apoptotic
cardiomyocytes (Salio et al., 2008). In contrast with these results,
PTX3 is deleterious in a model of ischemia and reperfusion of the
superiormesenteric artery, increasing tissue damage andmortality
(Souza et al., 2002, 2009), and accelerates lung injury in high tidal
volume ventilation in mice (Real et al., 2012). These data indicate
that PTX3 has a critical impact as ﬁne tuner of inﬂammation, with
both detrimental and beneﬁcial effects, depending on the nature
of the insult.
Different mechanisms may be involved in the regulatory func-
tions of PTX3 in inﬂammatory reactions. PTX3 binds to dying
neurons, rescuing them from irreversible damage and thus con-
ferring resistance to neurodegeneration. The higher resistance to
LPS observed in Ptx3-Tg mice has been attributed, at least in part,
to higher IL-10 and NO production by peritoneal macrophages
while a stronger deposition of complement component C3 was
observed in the infarct area of ptx3−/− mice, suggesting that the
modulation of the complement cascade likely contributes to the
cardioprotective role of PTX3 (Salio et al., 2008).
The protective role exerted by PTX3 in the lung injury and
pleurisy models is selectively linked to the capacity of PTX3 to
bind P-selectin, thus inhibiting leukocyte rolling on endothe-
lium. The N-linked glycosidic moiety of PTX3 is essential for the
interaction with P-selectin (Deban et al., 2010). In fact enzymatic
deglycosylation of PTX3 or site-directed mutagenesis of Asn220
(i.e., the N-linked glycosylation site) resulted in 70% reduction
of PTX3 binding to P-selectin. In addition lack of PTX3 glycosy-
lation reversed the inhibitory effect of the wild-type molecule in
the pleurisy model. Therefore, the regulatory function of PTX3
on inﬂammation is mediated by the protein glycosidic moiety,
which is reminiscent of some properties of the immunoglobulins
(Kaneko et al., 2006).
As mentioned above, PTX3 has an ambivalent role in the apop-
totic process in vitro. In vivo, ptx3−/− mice have a defective
capability to clear apoptotic T cells (Lech et al., 2011). In addition
lack of PTX3 on lupus prone genetic background (B6lpr) acceler-
ates the evolution of autoimmune lung disease, which is associated
to selective expansion of CD4/CD8 double negative “autoreactive”
T cells (Lech et al., 2011). Thus PTX3 may be also involved in res-
olution of inﬂammation through the complex role exerted on the
apoptotic process, this function being relevant for the control of
autoimmunity.
PATHOGEN RECOGNITION
Pentraxin 3 interacts with selected microbes, including fungi like
Saccharomyces cerevisiae, Paracoccidioides brasiliensis and conidia
from A. fumigatus, bacteria as Pseudomonas aeruginosa and Strep-
tococcus pneumoniae, and viruses, such as human and murine
cytomegalovirus (HCMV and MCMV) and the H3N2 inﬂuenza
virus (Garlanda et al., 2002; Diniz et al., 2004; Gaziano et al., 2004;
Bozza et al., 2006; Reading et al., 2008; Moalli et al., 2011a). Inter-
estingly, the binding of PTX3 to A. fumigatus conidia is abolished
in the presence of galactomannan, a major constituent of the
conidium wall, but not in the presence of dextran, galactose,
fucose, ormannose (Garlanda et al., 2002). However, a direct inter-
action between PTX3 and galactomannan has not been proved
as yet.
In vivo studies withPtx3-deﬁcientmice showed that PTX3 plays
non-redundant roles in innate resistance to infections caused by
these microorganisms, and for some of them the protective role
of PTX3 is mediated by complement. Ptx3-deﬁcient mice are
highly susceptible to invasive pulmonary aspergillosis, showing
high mortality (Garlanda et al., 2002). Ptx3-deﬁcient phagocytes
exhibit defective recognition and killing of conidia and the treat-
ment with recombinant PTX3 or neutrophil-associated PTX3
reverses this phenotype in vitro and in vivo (Garlanda et al., 2002;
Gaziano et al., 2004; Jaillon et al., 2007; D’Angelo et al., 2009).
The molecular mechanisms underlying the opsonic activity of
PTX3and increasedphagocytosis of conidia byneutrophils involve
Fcγ receptor II (FcγRII)-, CD11b-, and complement-dependent
mechanisms (Moalli et al., 2010). Indeed, PTX3 modulates differ-
ent effector pathways involved in innate resistance toA. fumigatus,
including complement activation (Bottazzi et al., 1997; Nauta
et al., 2003b; Deban et al., 2008; Ma et al., 2009) or promotion of
phagocytosis by interactingwith FcγRs,whichhave been identiﬁed
as pentraxin receptors (Lu et al., 2008).
Recent results indicate that PTX3 has therapeutic activity in
chronic lung infections by Pseudomonas aeruginosa, a major cause
of morbidity and mortality in cystic ﬁbrosis (CF) patients. Treat-
ment with recombinant human PTX3 causes enhanced clearance
of bacteria from the lungs of chronically infected mice, reduced
production of local pro-inﬂammatory cytokines and chemokines,
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neutrophil recruitment in the airways and histopathological
lesions. Also in this condition, the PTX3-dependent recognition
andphagocytosis of Pseudomonas aeruginosa involves the interplay
with complement and FcγRs (Moalli et al., 2011b).
Pentraxin 3binds to theoutermembraneproteinA (KpOmpA),
a major component of the outer membrane of Klebsiella pneu-
moniae (Jeannin et al., 2005), which interacts also with different
cellular PRMs, such as scavenger receptor lectin-like oxidized
low-density lipoprotein receptor-1 (LOX-1) and scavenger recep-
tor expressed by endothelial cell-I (SREC-I), and TLR2. The
recognition of this microbial component by PTX3 ampliﬁed the
inﬂammatory response through complement. Thus, recognition
and activation of several PRMs by KpOmpA lead to ampliﬁca-
tion of the cellular and humoral innate responses to this microbial
moiety (Jeannin et al., 2005; Cotena et al., 2007).
Bozza et al. (2006) studied the role of PTX3 in viral infections
and found that PTX3 binds both HCMV and MCMV, reduc-
ing viral entry and infectivity in DC in vitro. Consistent with
this Ptx3-deﬁcient mice are more susceptible to MCMV infec-
tion than wild-type mice and PTX3 protects susceptible BALB/c
mice from MCMV primary infection and reactivation in vivo as
well asAspergillus superinfection (Bozza et al., 2006). Recent stud-
ies also demonstrated that PTX3 binds to coronaviruses such as
murine hepatitis virus (MHV)-1/3 and reduced the infectivity of
MHV-1 in vitro. Moreover, Ptx3-deﬁcient mice showed enhanced
susceptibility to MHV-1 pulmonary infection and administration
of exogenous PTX3 accelerated viral clearance, reduced neutrophil
inﬂux and ameliorated lung injury (Han et al., 2012).
Perhaps the best characterized viral ligand of PTX3 is inﬂuenza
A virus (IAV) (Reading et al., 2008). Given the major focus of
this review and the prevalent role of PTX3 glycosylation in the
interaction with IAV, this topic will be discussed in a separate
chapter (see below).
The relevance of the role of PTX3 in infections in humans has
been demonstrated by Olesen et al. (2007), who recently showed
that polymorphisms within the PTX3 gene and in particular the
frequency of speciﬁc PTX3 haplotypes were signiﬁcantly differ-
ent in pulmonary tuberculosis patients as compared to healthy
individuals. Along the same line, Chiarini et al. (2010) showed
that the polymorphisms studied in tuberculosis correlated also
with the risk of Pseudomonas aeruginosa infections in CF patients.
PTX3 haplotype frequencies differed between CF patients colo-
nized or not by Pseudomonas aeruginosa, and a speciﬁc haplotype
was associated with a protective effect.
PTX3 AND INFLUENZA VIRUS
Pentraxin 3 acts as a sialylated glycoprotein inhibitor of IAVs both
in vitro and in vivo (Reading et al., 2008). The sialylated glycan of
PTX3 is recognized by the HA of susceptible IAV strains resulting
in inhibition of virus-induced hemagglutination and neutraliza-
tion of virus infectivity (Figure 2). In this way PTX3 acts as a
γ-type inhibitor, providing ligands that mimic the structure of
the cellular receptors used by IAV to attach to the surface of tar-
get cells. PTX3 also interacts with HA expressed on the surface
of IAV-infected cells and could therefore act as a direct opsonin,
or promote deposition of complement components, to facilitate
uptake and destruction by phagocytic cells expressing FcγRs or
complement receptors, respectively. Of interest, binding of the
viral HA to PTX3 also blocks the enzyme function of the viral neu-
raminidase (NA), the other major surface glycoprotein of IAV. By
inhibiting NA-mediated cleavage of sialic acids, PTX3 may inhibit
release of newly-formed virions from the surface of infected cells
in a manner analogous to that of NA-speciﬁc antibodies (Kil-
bourne et al., 1968) or NA inhibitor drugs (Gubareva et al., 2000).
Although enzymatic removal of sialic acid from PTX3 potentiates
its ability to activate the classical complement pathways (Inforzato
et al., 2006), desialylated PTX3 is not recognized by IAV and its
anti-IAV activity is lost (Reading et al., 2008).
Human ﬁcolins-1/2/3 bind IAV to neutralize virus infectivity
(Pan et al., 2012; Verma et al., 2012) and the antiviral activities
of ﬁcolins-1/3 are augmented in the presence of PTX3 (Verma
et al., 2012). PTX3 may also potentiate the anti-IAV activity of
other innate immune proteins. For example,MBLmediates potent
anti-IAV activity, including complement-mediated neutralization
and lysis of IAV-infected cells (Anders et al., 1994; Reading et al.,
1995) and complexes comprising MBL and PTX3 recruit C1q to
amplify complement activation via the classical pathway (Ma et al.,
2011). Conceivably, MBL–PTX3 hetero-complexes bound to IAV
virions and/or IAV-infected cells may also augment complement
activation to promote opsonization and/or lysis.
Attachment of IAV to the surface of target cells is mediated
by the viral HA, which recognizes terminal sialic acid residues
expressed by cell-surface glycoproteins and glycolipids. In general
terms, the HA of avian IAV prefers Neu5Acα2-3Gal-containing
receptors, which are expressed throughout the digestive and res-
piratory tracts of birds. In contrast, human IAV bind receptors
containing Neu5Acα2-6Gal, the predominant linkage expressed
by epithelial cells of the human upper airways (reviewed in Wilks
et al., 2012). In the 20th century, three subtypes of human IAV
(H1N1, H2N2, and H3N2) evolved from pandemic viruses of
1918, 1957, and 1968, respectively, and all originated from avian
viruses that transmitted to humans. Soon after their introduction
into humans in 1968, H3N2 IAV displayed dual HA speciﬁcity for
Neu5Acα2-3Gal and Neu5Acα2-6Gal (Ryan-Poirier et al., 1998),
but from 1975 onward isolates recognized only Neu5Acα2-6Gal.
Early H3N2 strains (1968–1973) were sensitive to PTX3 whereas
later strains (>1975) were resistant (Reading et al., 2008), consis-
tent with exclusive expression of Neu5Acα2-3Gal by recombinant
PTX3. To date, the antiviral activity of PTX3 against avian IAV
has not been reported. However, given the HA preference of avian
strains for Neu5Acα2-3Gal, the neutralizing activity of PTX3 in
human airways may represent an additional factor limiting inter-
species transmission. Moreover, in the ﬁrst years of a pandemic
when receptor speciﬁcity can be less strict (Ryan-Poirier et al.,
1998; Matrosovich et al., 2000), PTX3 may be one factor driving
evolution of human IAV with dual speciﬁcity toward preferential
recognition of Neu5Acα2-6Gal.
Given the HA-mediated receptor speciﬁcity, the PTX3 glyco-
sylation will be critical in determining its spectrum of anti-IAV
activities. Moreover, glycans terminating with sialic acid represent
attachment factors and/or receptor components formanydifferent
viruses (reviewed in Neu et al., 2011), suggesting that the γ-type
antiviral activity of PTX3 may not be limited to IAV. Recombi-
nant PTX3 expressing Neu5Acα2-3Gal mediates potent anti-IAV
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activity against certain H3N2, but not H1N1, virus strains in vitro
(Reading et al., 2008; Job et al., 2010). In addition to the speciﬁcity
of HA, the viral NA plays a critical role in determining PTX3 sen-
sitivity, as the sialic acid moiety on PTX3 must resist hydrolysis by
NA for neutralization to occur. Therefore, speciﬁcity and activity
of N1 versus N2 NA might be an additional factor contributing
to the differences observed in the sensitivity of H1N1 and H3N2
viruses to PTX3. PTX3 preparations from humanDCs and ﬁbrob-
lasts show heterogeneity in the relative amounts of bi-, tri-, and
tetrantennary glycans (Inforzato et al., 2006). Therefore, it will be
important to deﬁne the sialic acid content and linkage of natural
PTX3 from additional cellular sources (e.g., fromneutrophils) and
how this modulates the anti-IAV activity of PTX3.
Pentraxin 3 is highly conserved in evolution and murine and
human PTX3 are equally effective in mediating anti-IAV activ-
ity (Reading et al., 2008). PTX3 production is upregulated in
mice following IAV infection and Ptx3-deﬁcient mice are more
susceptible to a PTX3-sensitive H3N2 strain demonstrating the
importance of endogenous PTX3 in the murine model of IAV
infection. Moreover, treatment of wild-type mice with recom-
binant human PTX3 ameliorates virus replication and disease
severity in mice infected with PTX3-sensitive virus, providing
the ﬁrst evidence of the therapeutic potential of PTX3 against
IAV infections in vivo. In addition to binding IAV and facil-
itating virus clearance, PTX3 may also regulate inﬂammatory
responses to IAV infection in the lung and further studies are
required to deﬁne the mechanisms by which endogenous and
exogenous PTX3 ameliorate disease in the mouse model of IAV
infection.
CONCLUDING REMARKS
Pentraxin 3 is an evolutionary conserved element of the humoral
arm of the innate immune system, which plays a non-redundant
role in resistance against selected pathogens, such as A. fumigatus
and inﬂuenza virus (Garlanda et al., 2002; Reading et al., 2008). It
binds microbial moieties (Jeannin et al., 2005), orchestrates com-
plement activation (Doni et al., 2012), and has opsonic activity
(Moalli et al., 2010). The single N-linked glycosylation site present
in the molecule is occupied by complex type sialylated oligosac-
charides that have been shown to modulate PTX3 crosstalk with
a number of its ligands (i.e., complement components, inﬂuenza
virus, and P-selectin).
As a consequence, these data point to a critical role of glycosy-
lation in the modulation of PTX3 functions. It has been suggested
that PTX3 can act as double edged sword. Following binding to
microbial moieties, it has opsonic activity, activates complement
and enhances leukocyte recruitment. On the other hand, PTX3 per
se can act as a regulatorymolecule of innate immunity and inﬂam-
mationbydampening excessiveneutrophil recruitment. This latter
activity in particular is clearly dependent on PTX3 glycosylation
(Deban et al., 2010).
The ﬁnding of a regulatory function mediated by the glyco-
sidic moiety is reminiscent of similar activity of immunoglobulins
(Kaneko et al., 2006). Thus, molecules of the humoral arm of
the innate immune system, such as PTX3, and immunoglobulins,
share fundamental mechanisms of activity, including agglutina-
tion, complement activation, opsonization, and glycosylation-
dependent regulation of inﬂammation, despite the genetic and
structural differences between the two classes of molecules.
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